ODAC 30% Off Registration, Use Code: JDD30
Skip to main content
AestheticsFeatured Articles

Increased Trend of Cosmetic Procedures in Patients With Psoriasis Who Attain 75% or Greater Improvement

By August 25, 2020No Comments

Featured Article

Featured Article

A survey was conducted at a single dermatology center to determine if there was an increased trend in cosmetic procedures in patients with moderate to severe psoriasis who attained 75% or greater reduction of the body surface area (BSA) with biologic agents and oral systemic therapies, and if this was related to an improvement in quality of life following psoriasis clearance.

Read more

A survey was conducted at a single dermatology center to determine if there was an increased trend in cosmetic procedures in patients with moderate to severe psoriasis who attained 75% or greater reduction of the body surface area (BSA) with biologic agents and oral systemic therapies, and if this was related to an improvement in quality of life following psoriasis clearance.

Michelle E. Walters MD, Delphine J. Lee MD PhD, Paul S. Yamauchi MD PhD

Psoriasis is a chronic skin condition with a negative impact on patient quality of life. The National Psoriasis Foundation states that an acceptable response to psoriasis treatment is at least a 75% reduction in body surface area (BSA) at 3 months after initiation of treatment.

This reduction in BSA has been associated with improvement in quality of life, with clearance rates of clear to almost clear leading to an even greater improvement in quality of life.2,3 To date, there have been no studies examining the relationship between improvement in quality of life following a reduction in BSA, and the increased utilization of cosmetic procedures. Here, we examine the relationship between quality of life and the use of various cosmetic procedures in patients treated for psoriasis with systemic and biologic therapies who achieved at least 75% reduction in BSA.

This was a retrospective study assessing quality of life and the use of cosmetic procedures in psoriasis patients after attaining a75% or greater reduction of the body surface area with biologic agents only, systemic agents only, or a combination of both. This study was conducted according to the ethical guidelines of the 1975 Declaration of Helsinki. All patients provided informed consent.

Read Full Article Now
Article Cited in this Post

You May Also Like

Journal of Drugs in Dermatology JDD featuring Injectable NASHA Gel Skinbooster for Facial Skin Aging in Premenopausal and Postmenopausal Women With Estrogen Deficiency-Associated Not Receiving Hormone Therapy: A Case Series

Injectable NASHA Gel Skinbooster for Facial Skin Aging in Premenopausal and Postmenopausal Women With Estrogen Deficiency-Associated Not Receiving Hormone Therapy: A Case Series

| Aesthetics, Featured Articles, Latest News, Women | No Comments
Addressing Estrogen Deficiency Skin Aging: A Non-Hormonal Approach  Here is an insightful new study featured in the JDD! Intrinsic skin aging associated with estrogen deficiency presents a distinct therapeutic challenge…
Journal of Drugs in Dermatology JDD featuring Off-Label Uses of Nemolizumab: A Narrative Review

Off-Label Uses of Nemolizumab: A Narrative Review

| Atopic Dermatitis, Featured Articles, Latest News | No Comments
Beyond AD and PN: Expanding Horizons for Interleukin-31 Blockade in Treatment-Refractory Pruritus  Have you read this article from the JDD? Interleukin-31 receptor alpha targeting has established its place in our…
Journal of Drugs in Dermatology JDD featuring Skincare Mythbusters: The Real Science Behind Benzoyl Peroxide and Sunless Tanners

Skincare Mythbusters: The Real Science Behind Benzoyl Peroxide and Sunless Tanners

| Education, Featured Articles, Latest News, Medical Derm | No Comments
Unpacking clinical data on ingredient safety to separate viral fears from evidence-based facts Some of the most read topics in the JDD archive center on ingredient safety, and we want…

Leave a Reply